Gil Morgan MD

The OncoAlert Breast Cancer Faculty, led by Dr. Elisa Agostinetto🇧🇪 , has selected the OncoAlert🚨 TOP 🔟 #BreastCancer Abstracts to be presented at #ESMO25 in Berlin

See you in Berlin for #ESMO25!
The OncoAlert AF is ready to bring you all the great science coming out of Germany🇩🇪 .

We encourage you to follow these outstanding colleagues, and—as always—OncoAlert will be on the ground reporting in real time on all the latest news and trials.

A warm welcome to the 43rd Annual CFS, NOW VIRTUAL (LIVE OR ONLINE) !!
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) tinyurl.com/3ak6zm6s

A great 3 day conference for health care professionals focused on evidence-based, state-of-the-art cancer care. SIGN UP FOR FREE VIRTUAL REGISTRATION!

NEWS FROM INDUSTRY: UPDATE ON TROPION-Breast02 #BreastCancer
Source European Pharmaceutical Review, Astrazeneca, Daiichi Sankyo

www.europeanpharmaceuticalreview.com/news/266702/...

The phase III TROPION-Breast02 trial showed that the ADC Datopotamab Deruxtecandlnk significantly improved OS & PFS

Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysis

www.sciencedirect.com/science/arti...

The OncoAlert #GUCancer Faculty, led by Dr. Natalia Gandur🇦🇷 , Dr. Regina Barragan🇲🇽 & Dr. Gil Morgan🇺🇸 have selected the OncoAlert TOP🔟 #ESMO25 Abstracts In #ProstateCancer, #KidneyCancer #BladderCancer and #PenisCancer to be presented in Berlin🇩🇪 Picked using a Delphi System to establish our picks.

YouTube video by OncoAlert 360 Oncology Here and Now podcast (Breast Cancer) S02E03 w/ Dr. Erika Hamilton and Dr. Elisa Agostinetto

Oncology Here & NOW S2E3 in #BreastCancer
with @elisaagostinetto.bsky.social & @erikahamilton9.bsky.social discussing:

✅Current & emerging treatments
✅Patient selection
✅T-DXd + pertuzumab
✅ILD management & more
@hoperugo.bsky.social @elisabettabonzano.bsky.social
youtu.be/YdUX52c22Ig

A Great Day One of #IUCS25 Great Presentation by Dr. Partha Choudhury

The Theranostic Revolution
✨ Early randomized results look promising
🎯 Time to reimagine dosimetry & radionuclide choice for optimized delivery
#ProstateCancer

A Great Day One of #IUCS25 Great Presentation by Dr. Sara Rebuzzi 🇮🇹

⏸️ Treatment Breaks in #KidneyCancer – Key Takeaways
✅ Feasible in selected patients, with potential for long-term disease control
✅ Reduced toxicity burden vs continuous therapy
📊 Stronger evidence with ICI than TKI

Day2⃣of #IUCS25 🇬🇧Portsmouth
Dr. Enrique Grande 🇪🇸 discusses “Geting more patient the right 1st line in Bladder Cancer.”

👉 improving patient selection, refining dosing strategies, and developing predictive tools are key to making sure more patients receive and benefit the right first-line tx

Day2⃣of #IUCS25 🇬🇧Portsmouth

Dr. Petros Grivas🇺🇸 discusses “How Perioperative Treatment is Evolving in Bladder Cancer.”

📌 The perioperative space in MIBC is rapidly transforming—biomarkers, immunotherapy, ADCs, and combinations are reshaping the standard of care.

YouTube video by OncoAlert 360 OncoAlert Weekly Round Up🚨 Aug 29-Sept 4 Covering ASTER70, CodeBreak300 IMmotion010 and more

The OncoAlert WEEKLY RoundUp 🚨
Covering the TOP of the week Aug 28-Sept 4, 2025

REGISTER HERE👉 www.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...

youtu.be/maThWN36_sc
@elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @fumikochino.bsky.social @agerikssonmd.bsky.social

Experience the 2025 International Symposium of Gastrointestinal Oncology (ISGIO) LIVE in Austin Tx or Streamed ONLINE ! 👉 FREE HCP Registration (USE CODE: ONCOALERT )🚨
buff.ly/KVngjav

Join leading experts for two days of case-based learning, interactive panels, and cutting-edge updates in GI

You're invited to watch the Post-ASCO 2025 Lung Cancer Highlights webinar by @VJOncology 🫁 Watch Here 👉 bit.ly/4o14fdK

Featuring expert presentations and in-depth discussions on key abstracts in #Lungcancer presented at ASCO 2025.

🎯 Personalization in Cancer Care | OncoAlert Weekly Roundup (Breast, Bladder, GI, Lung, Prostate & More) Description: Welcome to this week’s OncoAlert Weekly Roundup—your 4-minute source for the… OncoAlert Weekly Roundup🚨 August 15-21, 2025 / AMPLIFY201, IMvigor011 Update in #BladderCancer

The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week August 15-21, 2025
youtu.be/4DAcGeK-Qac

REGISTER at ww.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...

Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma

www.sciencedirect.com/science/arti...

This international four-phase study (2022–2024) sought to modernize health-related quality of life (HRQOL) assessment tools

Join Our Collaborators at @SpringerIME to explore this new, FREE clinical pathway tool designed to help you detect and target NTRK fusions🧬 & HER2 mutations in #NSCLC 🫁 #LungCancer

CLICK HERE👉https://buff.ly/FeMbJ0r

Anti-PD-1 antibody (SCT-I10A) plus anti-EGFR antibody (SCT200) in patients with advanced esophageal squamous cell carcinoma: A multicenter, open-label, phase 1b clinical trial

acsjournals.onlinelibrary.wiley.com/doi/10.1002/...

YouTube video by OncoAlert 360 🎥 Precision Meets Practicality in Oncology | OncoAlert Weekly Roundup w/Gil Morgan July 19-24, 2025

The OncoAlert WEEKLY RoundUp 🚨
Covering the TOP of the week July 18-24, 2025

👉REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...

youtu.be/Jy2Wa2yMmMo

@elisaagostinetto.bsky.social
@elisabettabonzano.bsky.social
@icromeattini.bsky.social
@realbowtiedoc.bsky.social

@weoncologists.bsky.social summarizes the @oncoalert.bsky.social round-up 🤠

#SuppOnc dataon #GA the pillar assessment for #olderadults

#GIonc includes #agnostic treatments in #dMMR cancer 🧬

Be sure to not miss an update by signing up 🔗: oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...

YouTube video by OncoAlert 360 The TOP News THIS WEEK in Oncology July 4-10, 2025 : OncoAlert Weekly Round Up with Dr. Gil Morgan

The OncoAlert🚨Weekly Round Up Covering July 4-10, 2025
www.youtube.com/watch?v=ib45...
👉 REGISTER at www.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...

The #ASCO25 #OncoAlertTOP10 Abstracts in #LungCancer 🫁 These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago 🇺🇸

@biagioricciutimd.bsky.social
‬ @stephenvliu.bsky.social
@drsanjaypopat.bsky.social
Ping
@drjnaidoo.bsky.social

The #ASCO25 #OncoAlertTOP10 Abstracts in GI Oncology
These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸

@realbowtiedoc.bsky.social‬
@arosen380.bsky.social‬
Ping
‪@gillsharlene.bsky.social‬

Love the just in time education provided in the @oncoalert.bsky.social weekly roundup to keep me informed of the latest in cancer research!
TY @weoncologists.bsky.social !
#oncologynursing

The time is now! ⏰

Follow along for the best of #ASCO25

Top 10 trials in #GIonc and #pallonc are incoming 🔮

@oncoalert.bsky.social
@weoncologists.bsky.social
@pallonccop.bsky.social
@biagioricciutimd.bsky.social
@drnataliagandur.bsky.social
@elisabettabonzano.bsky.social
@kjankovic.bsky.social

YouTube video by OncoAlert 360 The OncoAlert Oncology Round Up May 15-22, 2025 Top Oncology Breakthroughs in less than 5 Min!

The OncoAlert🚨ROUND UP Now Out‼️
Covering May 15-22, 2025

REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...

youtu.be/xgIw0BISCpo

@elisaagostinetto.bsky.social
@barbaramelao.bsky.social
@elisaagostinetto.bsky.social
@icromeattini.bsky.social
@realbowtiedoc.bsky.social

Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single... Zanidatamab plus palbociclib and fulvestrant was generally safe and showed promising antitumour activity, supporting further evaluation of this chemotherapy-free triplet regimen.

Zanidatamab plus palbociclib and fulvestrant in previously treated patients with HR+, HER2+ metastatic #BreastCancer

www.thelancet.com/journals/lan...

Results support further investigation of this chemotherapy-free triplet approach as a potential tx option

@erikahamilton9.bsky.social

The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After D... Positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) radioligands has an established role in the assessment of recurrence…

Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence & Distant Metastases in Biochemical Recurrence of #ProstateCancer After Definitive Treatment

www.sciencedirect.com/science/arti...

Findings underscore importance of PSA stratification

Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer

ascopubs.org/doi/full/10....

analyzed individual data from 48 randomized trials in metastatic #ColorectalCancer to understand how tumor characteristics evolve across treatment lines

You're invited to join the Post-ASCO 2025 Breast Cancer Highlights webinar, hosted by VJOncology. Featuring expert presentations and in-depth discussions on key abstracts in #BreastCancer presented at ASCO 2025.

Register Here 👉 us06web.zoom.us/webinar/regi...

June 17, 2025
16:00–18:00 CEST